Novacyt (ALNOV.PA) Osake Kurssi

Novacyt SA primarily operates in the healthcare and biotechnology industries.

The main competitors of Novacyt SA in the market include companies such as PerkinElmer, Inc., Quidel Corporation, and Abbott Laboratories.

Novacyt SA is a renowned biotechnology company specializing in clinical diagnostics. Founded in 2006, Novacyt has since emerged as a global leader in the field. With a strong focus on research and development, the company has developed innovative solutions for the rapid detection and diagnosis of infectious diseases and various types of cancer. Novacyt's cutting-edge technology has gained recognition worldwide, enabling accurate and timely results. Through strategic partnerships and collaborations, Novacyt continues to expand its product portfolio and enhance its presence in international markets. With a commitment to improving global healthcare, Novacyt SA remains at the forefront of innovative diagnostics solutions.

Novacyt SA has achieved several significant milestones. Notably, the company developed and launched its NOVAprep® liquid-based cytology system, providing an innovative solution for cervical cancer screening. Furthermore, Novacyt SA successfully acquired Primerdesign Ltd, a molecular diagnostics company specializing in infectious diseases, expanding its product portfolio and market reach. The company also received Emergency Use Authorization from the US FDA for its COVID-19 testing kit, allowing for rapid and accurate diagnosis during the global pandemic. Novacyt SA's continuous commitment to innovation and strategic acquisitions has positioned it as a prominent player in the field of diagnostics and molecular testing.

Novacyt SA is primarily present in various countries and regions worldwide. As a global biotechnology company, Novacyt SA has established its presence in key markets such as Europe, including France, Germany, and the United Kingdom. Additionally, the company has expanded its operations into North America, with a strong focus on the United States. Novacyt SA also maintains a significant presence in other regions, including Asia, Latin America, and the Middle East. With its international reach, Novacyt SA is committed to serving the needs of customers and stakeholders across diverse geographies, contributing to its overall growth and success.

Novacyt SA is a leading international diagnostics company that prides itself on its commitment to high values and corporate philosophy. With a focus on innovation, Novacyt prioritizes providing accurate and reliable diagnostic solutions to improve global healthcare outcomes. The company's core values revolve around quality, integrity, and collaboration. Novacyt SA aims to meet the highest standards in every aspect of its operations, from research and development to manufacturing and customer support. By embracing a customer-centric approach and fostering partnerships, Novacyt SA strives to deliver impactful diagnostic solutions and contribute to the advancement of healthcare worldwide.

7 analyytikkoa arvioi tällä hetkellä Novacyt-osaketta: 0 suosittaa ostoa, 2 pitoa ja 5 myyntiä. Vuodelle 2026 analyytikot odottavat Novacyt-yhtiöltä 30,53 M GBP liikevaihtoa ja −0,13 GBP osakekohtaista tulosta.

Novacyt Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Novacyt-osake noteerataan hintaan 0,59 EUR (0,51 GBP).

Novacyt-osake (ALNOV.PA) on listattuna 8 pörssissä, muun muassa: London (NCYT.L), Frankfurt (NYZ.F), München (NYZ.MU), Düsseldorf (NYZ.DU), Paris (ALNOV.PA).

Novacyt SA is a multinational company that offers innovative diagnostic products and services for clinical diagnostics, life science research, and biopharmaceuticals. The company specializes in the development, manufacturing, and marketing of products for the diagnostics of infectious diseases and cancer. The core business of Novacyt SA is the development and marketing of molecular diagnostic tests for a variety of infectious diseases and types of cancer. The tests are specifically used for in vitro diagnostics and are based on polymerase chain reaction (PCR) technology. The tests are designed for rapid and accurate diagnosis of infectious diseases such as Covid-19, influenza, HIV, hepatitis, and tuberculosis, as well as cancer types such as prostate cancer and lung cancer. Novacyt SA operates in two business areas: diagnostics and biopharma. In the diagnostics sector, the company develops and markets molecular diagnostic tests used for the diagnosis of infectious diseases and cancer. The products of the diagnostics business include the NOVAprep cytology supplement and the RUBIDIUM radionuclide. In the biopharma sector, Novacyt SA produces and markets recombinant proteins and antibodies for research and development of innovative therapeutics and vaccines. The products of the biopharma business include purified beta-lactamase, cystatin C, and CD20, essential components for the development of cancer therapeutics and vaccines. Novacyt SA is focused on strengthening its market position in the diagnostics and biopharma sectors through the expansion of its portfolio of diagnostic tests and the development of new products for biopharma research. Additionally, Novacyt SA continuously conducts research and development activities to bring future products for the diagnosis of infectious diseases and types of cancer to the market. Novacyt SA has a strong presence in the global market and operates in over 100 countries worldwide. The company is oriented towards collaborating with partners in Europe, the Middle East, Africa, and Asia to market its products and services in different regions across the world. Overall, Novacyt SA has structured its business model around two pillars: molecular diagnostic tests and biopharma products. The company specializes in the development of products for the diagnostics of infectious diseases and cancer and aims to expand its presence in the global market and broaden its portfolio of diagnostic tests and biopharma products.

odotettu liikevaihto Novacyt on 30,53 M GBP. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Novacyt on −8,86 M GBP. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Novacyt:n hinta-voitto-suhde (P/E) on tällä hetkellä −4,04. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Novacyt-osakkeen arvostusta.

Novacyt:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,17. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Novacyt-osakkeen arvostuskennuslukuna.

Novacyt:n Eulpool-laatuscore on 2/10.

Novacyt:n ISIN on FR0010397232. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Novacyt:n WKN on A12CFH. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Novacyt:n ticker on ALNOV.PA. Tämä pörssinoteeraus käytetään Novacyt-osakkeiden kauppaan pörssissä.

Novacyt maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Novacyt kuuluu sektoriin 'Terveydenhuolto'.

Novacyt:n osingot jaetaan valuutassa GBP.